Rokeya Tasneen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11671552/publications.pdf

Version: 2024-02-01

430874 454955 1,771 30 18 citations h-index papers

g-index 37 37 37 1598 docs citations times ranked citing authors all docs

30

#	Article	IF	CITATIONS
1	Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial Agents and Chemotherapy, 2022, 66, e0239821.	3.2	15
2	Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 570-579.	5.6	10
3	GSK2556286 Is a Novel Antitubercular Drug Candidate Effective <i>In Vivo</i> with the Potential To Shorten Tuberculosis Treatment. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	12
4	Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0025321.	3.2	8
5	Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	17
6	Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	16
7	Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
8	Advancing the Therapeutic Potential of Indoleamides for Tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	12
9	Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	62
10	Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	23
11	Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	35
12	Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, $2018, 62, .$	3.2	37
13	Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. PLoS Neglected Tropical Diseases, 2018, 12, e0006728.	3.0	26
14	In Vivo-Selected Pyrazinoic Acid-Resistant <i>Mycobacterium tuberculosis</i> Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ACS Infectious Diseases, 2017, 3, 492-501.	3.8	33
15	Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61,	3.2	68
16	In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2017, 72, 2320-2325.	3.0	30
17	Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	4
18	Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. DMM Disease Models and Mechanisms, 2016, 9, 779-88.	2.4	49

#	Article	IF	CITATIONS
19	High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 4197-4205.	3.2	21
20	Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 270-277.	3.2	98
21	Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 129-135.	3.2	75
22	Reply to "Contradictory Results with High-Dosage Rifamycin in Mice and Humans― Antimicrobial Agents and Chemotherapy, 2013, 57, 1104-1105.	3.2	3
23	Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions. Journal of Infectious Diseases, 2012, 205, 595-602.	4.0	215
24	Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 4331-4340.	3.2	142
25	Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 5485-5492.	3.2	181
26	Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. Journal of Antimicrobial Chemotherapy, 2010, 65, 729-734.	3.0	49
27	Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2009, 53, 4178-4184.	3.2	90
28	Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 371-376.	5.6	118
29	Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2008, 52, 1522-1524.	3.2	203
30	Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2008, 52, 3664-3668.	3.2	106